The Effect of CORT118335 on Olanzapine-Induced Weight Gain

Inclusion criteria

• Body mass index 18.0 to 25.0 kg/m^2, inclusive
• Stable body weight as indicated by assessment at screening and pre-dose
• Able to swallow the size and number of tablets required
• Provide written informed consent and agree to adhere to study restrictions and contraception requirements.

Exclusion criteria

• Have received any investigational medicine in a clinical research study within the previous 3 months, or CORT118335 at any time
• Employee, or immediate family member of a study site or Sponsor employee
• Have a pregnant partner
• History of abuse of any drug or alcohol, or regularly consume more than 21 units alcohol/week
• Smokers or users of e-cigarettes and nicotine replacement products within the last 6 months
• Clinically significant abnormal results of clinical laboratory safety tests, electrocardiogram, or measurement of heart rate and blood pressure
• History of clinically significant cardiovascular, renal, hepatic, endocrine, metabolic, respiratory, or gastrointestinal disease, neurological or psychiatric disorder
• History of jaundice or gallstones or had a cholecystectomy
• Family history or known risk for narrow angle glaucoma
• Consumed liquorice or other glycyrrhetic acid derivatives regularly in the past 6 months
• Any condition that could be aggravated by glucocorticoid and/or mineralocorticoid antagonism (e.g., asthma, any chronic inflammatory condition, postural hypotension/orthostatic symptoms)
• Presence or history of clinically significant allergy
• Donation or loss of greater than 400 mL of blood within the previous 3 months
• Are taking, or have taken, any prescribed or over-the-counter drug within 14 days other than paracetamol or standard dose multivitamins. Longer restrictions apply for some medicines.
• Lactose intolerance.

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.